I DENTIFICATION of follistatin (F'S) as an activin-binding protein with the ability to neutralize activin's biological activity in numerous assays (l-3) has accelerated interest in both the biochemical and physiological aspects of this 32-to 39-kDa monomeric glycoprotein (4, 5). Although FS was originally purified from follicular fluid (FF) based on its ability to suppress FSH secretion from rat anterior pituitary cells (6, 7), the in zjiuo physiological actions of this hormone have yet to be identified.
This lack of information is due in large part to insufficiently sensitive and specific FS immunoassays until recently (8, 9) . Based largely on in vitro studies, however, it has been suggested that FS may act to regulate anterior pituitary hormone secretion (10-131, local gonadal actions of activin (14) (15) (16) (17) (18) (19) (20) , and/or act as a clearance mechanism for circulating activin (21, 22) . Significantly, all of these actions involve FS binding to and neutralizing activin's biological actions, i.e. no FS-specific action mediated by a cognate receptor has been identified.
On the other hand, biochemical and molecular biological analyses of follistatin have provided a wealth of information. In mammals, follistatin can be translated from either of two alternatively spliced messenger RNAs that results in translation of two variants distinguishable by whether they include protein sequence encoded by exon 5 (23), the smaller of which contains a core protein of 32 kDa (FS288) (24), while the larger contains a 35-kDa core (FS315) (5,24). In addition, this larger 315-amino acid form can be proteolytically processed at the C-terminus to FS300 or 303 (5,24). All of these forms can contain up to 2 carbohydrate chains, thus producing at least 6 known forms from a single gene product.
Importantly, the biochemical characteristics of these FS forms are not identical. For example, the full-length rhFS315 form is approximately lo-fold less bioactive than rhFS288 in the rat pituitary monolayer assay (5,24) as well as in ZJ~ZW (5). Although the activin-binding ability of rhFS288 and rhFS315 has been reported as equivalent, recent data using solid phase activin binding suggests that rhFS315 may have a slightly lower affinity for activin (24, 25) . In addition, the affinity of rhFS315 for heparin sulfate and cell surface proteoglycans was negligible compared to those of both FS303 and 288 (24), suggesting that differential posttranscriptional and/or posttranslational processing of FS might lead to functional differences.
As both FS and FS-activin complexes can bind reversibly to cell surface proteoglycans (24), these protein complexes may have important roles in the modulation of the autocrine or paracrine actions of activin. Based on complex formation with radiolabeled activin and inhibin, FS has also been identified as a binding protein for both molecules in serum and human FF (hFF) (21, 22, 26 The reproducibility of the serum activin binding peak in serum samples was similarly robust, as shown in Fig. 2 for four sequentially chromatographed male samples ( Fig. 2A) or female samples (Fig. 28) . The activin-binding protein peak in all subjects eluted in the same fraction, with a mean of 59.82% (SE, 0.884%) of the counts per min eluting within the activin peak (range, 58.0-62.3%), whereas for females, the mean was 63.18% (SE, 1.87%; range, 59.7-69.1%).
We, therefore, conclude that this pattern is typical of human serum. Recovery was assessed for activin added to buffer, serum, and hFF in an experiment similar to that shown in Fig. 1A . The results are shown in Table 1 for an additional 14-24 h at 4 C until chromatographed. Activin binding to pure rhFS288 was analyzed by adding 10 ng freshly reconstituted rhFS288 to 200 ~1 buffer A, followed by radioiodinated activin, and incubated as described for serum and hFF. We found that using freshly reconstituted rhFS288 was critical to the chromatography, as storage of rhFS288 at 4 C in buffer A resulted in FS-activin complexes of increasing size that eventually failed to enter the column.
Immunoprecipitation
Monoclonal antibodies were generated to rhFS288 and characterized (28 
Results

Chromatographic differences in serum and hFF FS
The relative elution positions of activin binding peaks in male and female sera and hFF, and of radiolabeled activin in equilibration buffer are shown in Fig. 1A . Although the serum activin binding peak in both sexes eluted at a fraction corresponding to an apparent M, of 60-70 kDa, the peak in hFF eluted at a fraction corresponding to an apparent M, of ZOO-300 kDa. This observation suggests that the stoichiometry and/or biochemistry of the FS-activin complex in these two fluids are fundamentally distinct. The elution position for rhFS288 complexed with labeled activin (Fig. 1B) was also earlier than that observed for serum and was similar to the FS-activin peak in hFF, demonstrating that the higher M, elution position of the hFF activin binding peak is a property shared by pure rhFS288. This was further investigated by adding 3 ng rhFS288 to normal male serum or hFF, followed by analysis of the resulting activin-binding peaks. As shown in Fig. lC , when rhFS288 was added to serum, the resulting complex eluted in an earlier fraction than the serum activin binding peak, where it appeared as a higher M, shoulder on the serum peak that now contained fewer counts. In contrast, the addition of 3 ng rhFS288 to hFF enhanced the area under the curve (AUC) of the existing hFF activin binding peak, which together now bound all available labeled activin. Thus, the elution position of the FS-activin complex appears to be an intrinsic biochemical property of the FS itself, perhaps in association with an additional factor present in hFF or serum. Furthermore, the activin binding peak in serum appears to be distinct from rhFS288 in this regard. No effect of pH adjustment on elution position was observed (Fig. 2D ) among fresh serum samples (pH 7.4), repeatedly frozen and thawed serum (pH 8.1), and stored hFF (pH 6.8).
We next investigated the degree to which the elution position of the serum activin binding peak varied between subjects. When sera from four normal males were analyzed in consecutive runs ( Fig. 2A) , the activin binding peak eluted in identical fractions with a mean AUC of 59.92 2 0.88% of the total counts per min eluted (range, 58.0-62.3%).
The activin binding peak in serum from one normal female and three females undergoing ovarian hyperstimulation for IVF (Fig. 2B ) also eluted at identical positions, and the mean AUC was 63.18 + 1.87% of the total counts per min eluted (range, 59.7-69.1%).
Although the total amount of radiolabeled activin bound varied more between female subjects than between males, the elution position of the activin binding peak was identical, supporting the concept that the elution position of the activin-binding protein in serum is an intrinsic biochemical property distinct from that in hFF.
Zmmunoprecipitation of FS
Differences between the activin binding peaks in serum and hFF were further investigated using monoclonal antibodies raised to rhFS288 (28). Immunoprecipitation from hFF with 200 pg/ml monoclonal 7FS30 overnight followed by Endo . 1996 Vd 137 . No 1 incubation with radiolabeled activin resulted in a 69% reduction in the AUC of the activin binding peak (Fig. 3A) . However, immunoprecipitation from human serum using 200 pg/ml of any of three separate anti-rhFS288 monoclonal antibodies followed by incubation with radiolabeled activin precipitated only 4% of the serum FS-activin complex peak (Fig. 3B) to 1 ml hFF (Fig. 4A) . In contrast, only 17% of the serum activin binding peak was extracted (Fig. 4B) Characterization of radiolabeled species in each binding protein peak. After chromatography as described above, activin binding peaks were immunoprecipitated using an antiactivin monoclonal antibody, then electrophoresed under reducing conditions. Lane A is radiolabeled activin without chromatography. Lane B is the activinactivin-binding protein complex in hFF. Lane C is free activin peak in that chromatographic run. Lane D is the activin-activin binding complex in serum, and lane E is free activin peak from that run. A major band at about 17 kDa is seen in all lanes, and a minor 1CkDa band is seen in A, B, and D. Although the identities of the two bands are unknown, they are probably forms of activin PA-subunit because they are both present in the radioiodinated activin before chromatography (A).
observed after immunoprecipitation of activin binding peaks from both serum (lane D) and hFF (lane B). These bands were identical to the activin bands observed when radiolabeled activin was electrophoresed without immunoprecipitation (lane A) as well as to the free activin peaks from serum (lane E) and hFF (lane C). These observations demonstrate that activin's shift to a higher M, elution volume when added to either hFF or serum is indeed due to activin complexing with binding proteins.
Chromatography of rhFS315
To investigate the hypothesis that the serum activin binding peak elutes from the Superose column later than the hFF peak because it is more like rhFS315 than rhFS288 and is unable to form high M, complexes, FS315 cDNA was stably expressed in CHO cells. The activin binding peak of rhFS315-conditioned medium elutes identically to that of human serum under a variety of loading conditions (Fig. 6A) . Furthermore, like serum, sulfate Cellufine extracted only 19% of the activin binding peak from the rhFS315-conditioned medium (Fig. 6B) . Finally, only 10% of the activin binding peak in rhFS315-conditioned medium was immunoprecipitated by 200 pg anti-rhFS288 monoclonal antibodies (Fig. 6C) . It would appear from these data, then, that the activin-binding protein in rhFS315-conditioned medium has biochemical and immunochemical properties similar to those of human serum, but distinct from those of rhFS288 and hFF.
Discussion
Using gel filtration chromatography, we demonstrated differences in apparent M, for the activin binding peak in serum and hFF, as determined by the shift in elution position of radiolabeled activin after incubation with these physiological fluids. Specifically, the activin binding peak in hFF 6 . Chromatography of recombinant hFS315-conditioned medium. A, FS315 was expressed in CHO cells, and the activin-binding protein peak in the conditioned medium eluted at an apparent M, identical to that in male serum (60-70 kDa), suggesting that the serum activin-binding protein peak is full-length and FS315-like. Conditioned medium from untransfected wild-type (WT) CHO cells was used as a control. B, As observed in serum (see Fig. 3 ), only 19% of the rhFS315 activin binding peak was extractable using sulfate Cellufine under conditions that removes almost all of the FS in hFF and rhFS288. C, Again, as observed with serum, 200 Fg/ml antirhFS288 monoclonal antibody immunoprecipitated only 10% of the activin binding peak from hFS315conditioned medium.
serum, the radiolabeled activin peak elutes at an apparent M, of 60-70 kDa. The present studies thus demonstrate that the serum activin-binding protein differs from that in hFF based upon several findings. The activin binding peaks in hFF and rhFS288 both elute at an apparent M, greater than that of serum, can be immunoprecipitated with monoclonal antibodies to rhFS288, and are removed by sulfate Cellufine affinity precipitation. The identity of the serum activin binding peak, however, is more problematic. It is likely to be FS based on the fact that the serum binding protein peak shows nearly irreversible activin binding kinetics, as observed for hFF and rhFS288 (27), a unique property among activin's binding proteins.
In addition, the elution position of the serum activin binding peak is identical to that of rhFS315-conditioned medium. Finally, previous investigators demonstrated that this lower mol wt peak in serum is FS based upon affinity and size criteria, and was easily distinguishable from the very high M, (750,000 kDa) a,-macroglobulin peak (21, 22, 26, 32 
